检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:冷冰[1] 李荷欢[1] 韩思源[1] 贺佳妮[1] 刘晓颖[1] 郝永红[1] 刘伟[1] 朱全超[1] 杨庆燕[1]
机构地区:[1]中国医科大学附属第一医院整形外科,辽宁沈阳110001
出 处:《中国美容整形外科杂志》2010年第12期764-766,共3页Chinese Journal of Aesthetic and Plastic Surgery
摘 要:目的 探讨己酮可可碱对随意皮瓣移植术后皮瓣成活情况的影响.方法 以40只Wistar大鼠作为实验动物模型,制作大鼠背部随意皮瓣(长宽比例为3∶1),随机分为两组(A为实验组,B为对照组).实验组在切取皮瓣术后给予己酮可可碱50mg/kg,1次/d腹腔注射,连续给药7 d;对照组给予腹腔注射0.9%生理盐水.术后第1、3、5、7天检测各组动物随意皮瓣的血流速度,并取蒂部全血,检测全血黏度,红细胞聚集指数和血沉;观察术后第1、3、5、7天各组皮瓣坏死面积并计算皮瓣坏死率.结果 两组皮瓣坏死率及血液流变学指标比较,实验组与对照组相比,其皮瓣坏死率明显降低,血液流变学指标得到有效改善.结论 己酮可可碱可明显提高血流速度,改善随意皮瓣血液流变性,降低随意皮瓣坏死率.Objective To investigate the effect of Pentoxifylline on free flap. Methods Forty Wistar rats were chosen as the experimental models and free flaps were harvested from the back of the rats, which as pect ratio was 3: 1. Then they were divided into two groups randomly. Group A was as the experimental group, receiving drug treatment. Group B was as the control group. Rats in the Group A were treated with intraperitoneal injection of 50 mg/kg Pentoxifylline, once a day, 7 days successive administration. The control group was given 0.9% sodium chloride treatment. Blood flow velocity, blood viscosity, aggregation erythrocyte aggregation index and erythrocyte sedimentation rate in each group were measured at 1,3,5,7 days after treatment. Necrosis area of the free flaps and necrosis rate of the flap at 1,3,5,7 days after treatment were also measured and calculated respectively. Results Compared with the control group, the necrosis rate decreased, and the indexes of the hemorheology, such as blood flow velocity, blood viscosity, erythrocyte aggregation index and erythrocyte sedimentation rate improved effectually. Conclusion Pentoxifylline can increase markedly blood flow velocity, improve the hemorheology and decrease the necrosis rate of the free flaps.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.70